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on initial presentation. Thus, these relapses
maybe due tonewoccurrences ofdisease.
These and other studies ofleukaemias and
lymphomata were described and the implica-
tions of the results for the causes of the
malignancies were discussed.
Review Paper: FIAKLOW, P. J., July 4, 1974. The
Origin and Development of Human Tumours
Studied with Cell Markers. New Engl. J. Med.,
291, 26.
CULTURED LYMPHOBLASTOID
LINES AS A MODEL FOR
LEUKAEMIA/LYMPHOMA
C. M. STEEL, M.R.C. Clinical and Population
Cytogenetics Unit, Edinburgh.
With certain notable exceptions, the
lymphoblastoid cell lines established from
biopsies of Burkitt's lymphoma appear, on
cytogenetic and biochemical analysis to be
representative of the tumour cells in this
condition (Gripenberg, Levan and Clifford,
1969; Klein et al., 1968; Fialkow et al.,
1971). Similar lines derived from other
sources have the property of indefinite
proliferation in vitro and may therefore
provide a model for the study ofat least some
aspects of malignancy.
Though little is yet known of the mech-
anisms involved in the transition from
normal lymphocyte to lymphoblastoid cell,
there are consistent differences between the
two cell types which may provide clues to the
nature ofthe transformation process.
Many established lines have a high level of
steroid-binding protein which is also a
characteristic of the malignant cells in acute
lymphoblastic leukaemia. Preliminary data
suggest however that the cytolytic effect of
steroids on some lymphoblasts is not depen-
dent solely on the presence of steroid recep-
tors (Gailani et at., 1973; Lippmann, Berry
and Thompson, 1974).
Changes in the expression of surface
antigens may have an important role in
protection ofthehost againstthe proliferation
of abnormal lymphoid cells in vivo (Golub
et al., 1972; Steel et al., 1974). The antigenic
changes have yet to be fully characterized
but HL-A typing reveals both qualitative
and quantitative alterations in the expression
of transplantation antigens when a cell line
becomes established in culture. Similar
changes have been detected on leukaemic
cells in vivo.
Serial studies on lymphoblastoid lines
show progressive shifts in the expression of
transplantation antigens (Dick et al., 1973).
Other characteristics, including karyotype,
immunoglobulin synthesis and isoenzyme
pattern, also change with time in culture
(Steel, McBeath and O'Riodan, 1971; Evans,
Steel and Arthur, 1974; Povey et al., 1973).
On following genetic markers in individual
lines it is clear that the bulk population in
vitro changes by the emergence of successive
waves of clones. If this is a valid model for
the behaviour ofmalignant cells in vivo it has
important implications for therapy.
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B AND T CELL MEMBRANE
MARKERS IN HUMAN LEUKAEMIAS
AND LYMPHOMATA
M. SELIGMANN, J. C. BROIUET AND J. L.
PREUD'HOMME, Research Institute for Blood
Diseases, HIopital Saint-Louis, Paris.
Cells from patients with leukaemias were
studied using mainly surface immuno-
globulins and IgG aggregates as B cell
markers, spontaneous rosette formation with
sheep red cells and cytotoxic and immuno-
fluorescence tests using heterologous antisera280 REPORT OF THE LEUKAEMIA RESEARCH FUND
for identifying T cells. The vast majority of
chronic lymphocytic leukaemias (CLL) was
shown to be a monoclonal B cell proliferation
with a maturation block. However biclonal
proliferations were encountered and a T cell
origin was proven in 3 out of 150 CLL. The
abnormal cells in 14 patients with the Sezary
syndrome were identified as T cells. In most
patients with common acute lymphoblastic
leukaemia, no B or T markers were detected
at the surface of the abnormal cells. These
cells possessed neo antigens reactive with non
anti-B antibodies present in antisera to CLL
cells. In 30% ofthe cases the T nature ofthe
blast cells appeared likely. In 11 other ALL
patients a monoclonal B cell proliferation was
found. These patients were usually not
affected with common ALL and belonged
mostly to two specific entities; in 3 cases the
blastic proliferation supervented in patients
previously affected with common CLL and in
6 cases the blast cells possessed all the
cytological features ofBurkitt's tumour cells.
B and T cell markers were also assessed in
more than 30 cases ofnon-Hodgkin malignant
lymphomata. Well-differentiated lympho-
cytic lymphomata and nodular lymphomata
were found to be ofB cell origin. Most ofour
cases of diffuse poorly differentiated lympho-
cytic lymphoma behaved as B cell monoclonal
malignancies. The so-called reticulum cell
sarcomata probably represent a hetero-
geneous group. In most cases the large
malignant cells appeared to be devoid of B or
T cellmarkers. However in one case a strong
affinity receptor for IgG was found and was
suggestive of a true histiocytic origin. In 3
patients in whom reticulum cell sarcoma
supervened on a previous lymphoid malig-
nancy (chronic lymphocytic leukaemia or
Waldenstrom macroglobulinaemia) the large
sarcoma cells belonged to the B cell series and
presumably originated from the same clone as
the previous lymphoid proliferation sincethey
bore the same immunoglobulin chains.
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SURFACE ANTIGENS OF
LEUKAEMIC CELLS
M. F. GREAVES, University College London.
Over the past few years the development
ofthe technology for identifying the selective
expression of cell surface markers on various
populations oflymphoid cellshas been a major
contribution towards our current under-
standing of the organization and function of
the immune system (Greaves, Owen and Raff,
1973). Inprinciplethisapproachshouldalsobe
applicable to the analysis of leukaemias,
lymphomata and in fact malignant cells in
general. Thus ifa panel ofcell surface markers
is available which in combination provide a
cell surface phenotype characteristic of a par-
ticular lymphocyte cell type, say a T cell, then
the presence of a similar cell surface profile on
a leukaemic cell might be taken to indicate
that the latter may have arisen from T cells.
This type of investigation might provide a
cell refinement to the diagnosis of lympho-
reticular malignancies and also insight into
the origin and aetiology of the disease
(Brown et al., 1974; Harris, 1973).
Another approach to the identification of
leukaemic cells which may hold out even
more promise involves the use of antisera
which may define cell surface antigens of
leukaemic cells which are either entirely
restricted to those cells or are at least absent
from normal lymphoreticular cells. There is
a long history of attempts to produce such
discriminating antisera (reviewed in Harris,